equipment, including certain medical devices.

Substance of Very High Concern (SVHC): Chemicals with carcinogenic, mutagenic, reproductive, or persistent properties under REACH.

Authorisation: Requirement under REACH to obtain permission for using certain SVHCs in manufacturing.

Exemptions: RoHS exemptions granted to specific medical or pharma devices under strict conditions.

These definitions form the compliance foundation for pharma and medtech supply chains in the EU.

Global Frameworks and Pharma Impact

While REACH and RoHS are EU-specific, their influence extends globally:

• EU: Direct applicability in all member states; non-compliance can block access to the EU market.
• US: No direct REACH equivalent, but EPA’s Toxic Substances Control Act (TSCA) imposes similar requirements.
• India: Draft Chemical (Management and Safety) Rules 2020 align closely with REACH for imports/exports.
• China: China REACH (MEE Order 12) imposes similar registration and notification obligations.
• ROW Markets: Countries like Korea (K-REACH) and Japan (CSCL) mirror EU chemical safety approaches.

RA professionals must consider REACH and RoHS equivalents worldwide, especially in global supply chain planning for APIs, excipients, and packaging materials.

Processes and Workflow for REACH and RoHS Compliance

A structured compliance workflow ensures pharmaceutical companies meet REACH and RoHS obligations:

1. Substance Inventory: Identify all chemicals, excipients, packaging materials, and device components used in EU markets.
2. Classification: Assess whether substances fall under REACH registration or RoHS restricted lists.
3. Data Collection: Compile toxicological, ecotoxicological, and physicochemical data for REACH dossiers.
4. Submission: Register substances with ECHA and ensure notified bodies review device components for RoHS compliance.
5. Risk Assessment: Conduct chemical safety assessments and exposure evaluations.
6. Post-Market Monitoring: Update REACH registrations with new data and maintain RoHS conformity declarations.

This workflow emphasizes early identification, robust documentation, and continuous monitoring for compliance sustainability.

Case Study 1: REACH Registration for Excipient

Case: In 2022, a European pharma manufacturer importing >10 tonnes of an excipient annually into the EU needed REACH registration.

• Challenge: Lack of full toxicological data from the supplier.
• Action: Collaborated with consortium to share data and submit a joint REACH registration.
• Outcome: ECHA accepted dossier, ensuring uninterrupted supply.
• Lesson Learned: Supplier collaboration is critical for REACH compliance in pharma.

Case Study 2: RoHS Compliance for Medical Device

Case: A drug-delivery device manufacturer sought CE marking under EU MDR in 2023.

• Challenge: Device components contained lead above RoHS thresholds.
• Action: Applied for RoHS medical device exemption while reformulating the component.
• Outcome: CE marking granted under MDR with RoHS exemption, followed by compliant redesign.
• Lesson Learned: RoHS exemptions provide short-term solutions, but redesign ensures long-term compliance.

Tools, Templates, and Systems Used

Pharmaceutical companies rely on specific resources for REACH and RoHS compliance:

• ECHA IUCLID Software: Standard tool for preparing and submitting REACH dossiers.
• RoHS Compliance Checklists: Templates for restricted substances in devices and packaging.
• Material Safety Data Sheets (MSDS): Central repository of chemical safety data.
• Supply Chain Auditing Tools: Digital platforms for verifying supplier compliance with REACH/RoHS.
• Regulatory Information Management (RIM) Systems: Track compliance obligations across jurisdictions.

These tools help streamline compliance documentation and ensure readiness for inspections.

Common Challenges and Best Practices

RA professionals face several hurdles in implementing REACH and RoHS compliance:

• Data Gaps: Limited availability of toxicological data for certain excipients or raw materials.
• Supply Chain Complexity: Multiple global suppliers complicate compliance tracking.
• Regulatory Variability: Differences in EU, US, and Asian frameworks create duplication of effort.
• Resource Burden: REACH registration and RoHS conformity assessments are resource-intensive.

Best practices include building compliance into procurement contracts, using harmonized templates, training suppliers, and conducting periodic audits.

Latest Updates and Strategic Insights

By 2025, REACH and RoHS regulations are shaping pharma ESG strategies:

• REACH SVHC Expansion: More chemicals added annually, increasing registration obligations.
• RoHS Scope Expansion: New substances such as phthalates added, impacting medical devices.
• Digital Compliance Platforms: Adoption of AI-powered compliance tracking tools.
• Global Harmonization: Convergence of REACH-like regulations in Asia and Latin America.
• ESG Integration: Investors and regulators demanding evidence of REACH and RoHS compliance in sustainability reporting.

Strategically, RA professionals must align REACH and RoHS compliance with ESG goals, demonstrating regulatory responsibility and environmental stewardship.

Conclusion

REACH and RoHS regulations extend beyond traditional environmental laws, directly impacting pharmaceutical manufacturing, medical devices, and global supply chains. By mastering registration processes, leveraging compliance tools, and harmonizing with global equivalents, RA professionals can safeguard market access and ESG credibility. In 2025 and beyond, REACH and RoHS compliance will be an integral part of pharma’s sustainability and regulatory strategy.